Evaluating serdexmethylphenidate and dexmethylphenidate capsules as a once-daily treatment option for ADHD
- PMID: 37226489
- DOI: 10.1080/14656566.2023.2218544
Evaluating serdexmethylphenidate and dexmethylphenidate capsules as a once-daily treatment option for ADHD
Abstract
Introduction: Attention deficit/hyperactivity disorder (ADHD) is a common behavioral disorder which is best treated through a combination of medication and behavioral therapy, with stimulant medications serving as a first-line treatment approach. Serdexmethylphenidate (SDX), a prodrug of dexmethylphenidate (d-MPH), a commonly utilized stimulant medication, has recently received approval and is marketed in the U.S.A.
Areas covered: This review summarizes peer-reviewed literature on SDX published between 2021-2023 and a review of data available from ClinicalTrials.gov.
Expert opinion: SDX represents a new option for treatment for ADHD. It is unique in its prodrug design and achieves a relatively extended duration of action in comparison to other stimulant formulations. Although the research is relatively limited thus far, early data suggests it to be a safe medication to consider with side effects being similar to other stimulant medications. Its prodrug design is useful in potentially serving as a deterrent to intentional parenteral abuse and its ability to be opened and sprinkled makes it an option for those individuals with ADHD who might be unable to swallow pills.
Keywords: ADHD; dexmethylphenidate; prodrug; serdexmethylphenidate; stimulant medication.
Similar articles
-
Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study.J Child Adolesc Psychopharmacol. 2023 Mar;33(2):51-58. doi: 10.1089/cap.2022.0076. Epub 2023 Feb 20. J Child Adolesc Psychopharmacol. 2023. PMID: 36809150 Free PMC article. Clinical Trial.
-
Dose Proportionality and Steady-State Pharmacokinetics of Serdexmethylphenidate/Dexmethylphenidate, a Novel Prodrug Combination to Treat Attention-Deficit/Hyperactivity Disorder.J Child Adolesc Psychopharmacol. 2022 Jun;32(5):288-295. doi: 10.1089/cap.2022.0015. Epub 2022 Jun 3. J Child Adolesc Psychopharmacol. 2022. PMID: 35666231 Free PMC article.
-
Analysis of Growth Velocity in Children with Attention-Deficit/Hyperactivity Disorder Treated for up to 12 Months with Serdexmethylphenidate/Dexmethylphenidate.J Child Adolesc Psychopharmacol. 2023 May;33(4):134-142. doi: 10.1089/cap.2023.0012. J Child Adolesc Psychopharmacol. 2023. PMID: 37204277 Free PMC article. Clinical Trial.
-
Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder.Am J Health Syst Pharm. 2014 Jul 15;71(14):1163-70. doi: 10.2146/ajhp130638. Am J Health Syst Pharm. 2014. PMID: 24973373 Review.
-
Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder.CNS Drugs. 2009 Dec;23(12):1057-83. doi: 10.2165/11201140-000000000-00000. CNS Drugs. 2009. PMID: 19958043 Review.
Cited by
-
A decade of pyridine-containing heterocycles in US FDA approved drugs: a medicinal chemistry-based analysis.RSC Med Chem. 2024 Oct 10;16(1):12-36. doi: 10.1039/d4md00632a. Online ahead of print. RSC Med Chem. 2024. PMID: 39493227 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical